

**Table S1** The chemotherapy information for the NCRT group

| Chemotherapy regimen | Drug name      | Dose (mg/m <sup>2</sup> ) | Administration frequency | Days per cycle | Number of patients | Number of cycles |
|----------------------|----------------|---------------------------|--------------------------|----------------|--------------------|------------------|
| TP regimen           | Cisplatin      | 75–80 mg/m <sup>2</sup>   | d1                       | q3w            | 101                | 2–4              |
|                      | Carboplatin    | AUC 5                     | d1                       | q3w            | 79                 | 2–4              |
|                      | Nedaplatin     | 80–100 mg/m <sup>2</sup>  | d1                       | q3w            | 49                 | 2–4              |
|                      | Nab-paclitaxel | 125–260 mg/m <sup>2</sup> | d1                       | q3w            | 163                | 2–4              |
|                      | Paclitaxel     | 135–175 mg/m <sup>2</sup> | d1                       | q3w            | 41                 | 2–4              |
|                      | Docetaxel      | 75 mg/m <sup>2</sup>      | d1                       | q3w            | 25                 | 2–4              |
| PF regimen           | Cisplatin      | 75 mg/m <sup>2</sup>      | d1–3                     | q3w            | 23                 | 2–4              |
|                      | Capecitabine   | 80 mg/m <sup>2</sup>      | po bid d1–14             | q3w            | 12                 | 2–4              |
|                      | 5-FU           | 800 mg/m <sup>2</sup>     | d1–5                     | q3w            | 11                 | 2–4              |

**Table S2** The treatment information for the NICT group

| Treatment plan                                                                                                                                          | Days per cycle | Number of cycles | Number of patients |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------------------|--------------------|
| Camrelizumab (200 mg, d1); nab-paclitaxel (100 mg/m <sup>2</sup> , d1); S-1 (60 mg/m <sup>2</sup> /d, d1–14); nedaplatin (85 mg/m <sup>2</sup> ) (d1–3) | q3w            | 2–4              | 20                 |
| Camrelizumab (200 mg, d1); nab-paclitaxel (260 mg/m <sup>2</sup> (d1, 8); cisplatin (60–80 mg/m <sup>2</sup> , d1)                                      | q3w            | 2–4              | 17                 |
| Camrelizumab (200 mg, d1); nab-paclitaxel (260 mg/m <sup>2</sup> ) (d1, 8); nedaplatin (50–80 mg/m <sup>2</sup> , d2)                                   | q3w            | 2–4              | 21                 |
| Camrelizumab (200 mg, d1); nab-paclitaxel (260 mg/m <sup>2</sup> ) (d1 or d1, 4); nedaplatin (85 mg/m <sup>2</sup> ) (d1–3)                             | q3w            | 2                | 70                 |
| Sintilimab (200 mg iv d1); nab-paclitaxel (260 mg/m <sup>2</sup> iv d1); nedaplatin (50–80 mg/m <sup>2</sup> iv d2)                                     | q3w            | 2–4              | 60                 |
| Tislelizumab (200 mg iv d1); paclitaxel (260 mg/m <sup>2</sup> iv d1); cisplatin (60–80 mg/m <sup>2</sup> iv d1 or d2)                                  | q3w            | 2–3              | 15                 |